Prosperity Financial Group Inc. Sells 225 Shares of Zoetis Inc. (NYSE:ZTS)

Prosperity Financial Group Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,945 shares of the company’s stock after selling 225 shares during the quarter. Prosperity Financial Group Inc.’s holdings in Zoetis were worth $771,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in ZTS. Mizuho Securities USA LLC increased its position in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the period. Bank of New York Mellon Corp raised its holdings in Zoetis by 4.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after purchasing an additional 178,303 shares in the last quarter. Clearbridge Investments LLC boosted its position in Zoetis by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after acquiring an additional 166,517 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Zoetis by 17.3% in the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after acquiring an additional 351,372 shares in the last quarter. Finally, Sarasin & Partners LLP raised its holdings in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.1 %

Shares of ZTS opened at $176.96 on Monday. The stock’s 50-day moving average price is $185.62 and its 200-day moving average price is $180.72. The company has a market capitalization of $79.84 billion, a price-to-earnings ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.36 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ZTS shares. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.